The German biotech company CureVac he confirmed that the final results of clinical trials on the efficacy of its expected mRNA vaccine against the coronavirus are rather disappointing. In fact, the CureVac vaccine has been shown to have an efficacy of 48 percent, much lower than that of other vaccines already authorized that use the same technology, namely those of Pfizer-BioNTech and Moderna.
Tests on the CureVac vaccine involved 40,000 volunteers in South America and Europe, 228 of whom developed symptoms related to COVID-19 over the course of the trial: 83 received the vaccine and 145 a substance that does nothing (placebo). This vaccine was slightly more effective in the young population, those between 18 and 60, where it showed 53 percent effectiveness against mild or moderate symptoms, and was 100 percent effective in preventing more severe symptoms. and death from causes related to the disease caused by the coronavirus.
Unlike the Pfizer-BioNTech and Moderna vaccine trials, the CureVac tests were carried out while 15 coronavirus variants were already in circulation: genetic tests on volunteers who developed symptoms of COVID-19 during the trial showed that only 3 percent of the cases were related to the first versions of the virus circulating early last year.
– Read also: What the first results of the CureVac vaccine said
–
